Outlook Therapeutics (OTLK) has disclosed a new risk, in the Natural and Human Disruptions category.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Outlook Therapeutics’ operations could be significantly disrupted by the advent of disease outbreaks, epidemics, or pandemics, particularly in regions crucial for their clinical trials and business functions. Such health crises pose a threat to the initiation and continuation of clinical trials, like the COVID-19 related delay in patient enrollment for NORSE TWO, potentially leading to increased costs, extended timelines, and regulatory approval setbacks. Supply chain complications during these times could further impede the availability of essential medical supplies for trials. The unpredictability of such events amplifies the uncertainty surrounding Outlook Therapeutics’ operational and financial projections.
The average OTLK stock price target is $2.00, implying 372.70% upside potential.
To learn more about Outlook Therapeutics’ risk factors, click here.
